TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohn's Patients
November 10th, 2009
New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA=AE (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years. In a separate analysis, CIMZIA significantly improved patients' symptoms as early as day 8 as reported in a post-hoc responder analysis of PRECiSE 2, the original double-blind placebo controlled study. These data from PRECiSE 2 and the open-label extension PRECiSE 3 studies are being presented this week at the...
Source: TB & Outbreaks Week (2009-11-10)
|
